Although significant advances have been made recently in the chemotherapy of AIDS, the presently available, clinically useful anti-AIDS agents target only two biological macromolecules, reverse transcriptase and protease. Therefore, new anti-AIDS agents are needed which will interact with additional viral targets important in the replication cycle of the virus. These new agents with novel mechanisms of action can be expected to enhance the prospects for successful treatment of AIDS by combination chemotherapy. Recent work by this Principal Investigator and his associates has involved the design and synthesis of cosalane, a novel anti-HIV agent which inhibits the binding of CD4 to gp120 and inhibits the cytopathic effects of HIV-1 and HIV-2 in cell cultures. Although enthusiasm surrounding the antiviral activity of cosalane is high, the potential therapeutic use of cosalane is restricted by low oral bioavailability and unoptimized potency. The present application is for support to design and synthesize certain cosalane analogs which will broach these remaining problems. In order to address the problem of low oral bioavailability, a series of cosalane analogs and prodrugs is proposed in which the compounds are designed to have enhanced oral absorption and increased metabolic stability. The metabolism of these compounds will be studied in rat intestinal and hepatic microsomal systems as well as by mesenteric and systemic blood sampling in whole animals. The pharmacokinetics will be defined, the structures of the metabolites will be determined, and the metabolites will be synthesized. The design and synthesis of more potent cosalane analogs is also being carried out. These efforts are being assisted by computer graphics molecular modeling of hypothetical ligand-protein complexes, as well as by analysis of the available information concerning the structural parameters associated with the biological activities of the cosalane analogs synthesized to date. The cosalane congeners will be examined for a number of biological activities, including: (1) prevention of HIV-1 cytopathicity in cell culture; (2) cytotoxicity; (3) inhibition of syncytium formation; (4) inhibition of virion binding to cells; (5) CD4 binding; (6) gp120 binding; (7) inhibition of gp120-CD4 binding; (8) HIV-1 RT inhibition; (9) inhibition of integrase; (10) inhibition of protease; (11) effect of time of addition, limited treatment, and preincubation on activity; (12) effects on virus production; (13) stability in serum and serum protein binding; and (14) activity in an in vivo hollow fiber animal model.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI036624-04
Application #
2544495
Study Section
Special Emphasis Panel (ZRG5-ARRB (01))
Project Start
1995-04-01
Project End
2001-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Purdue University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Johnston, Thomas P; Kuchimanchi, Kamesh R; Alur, Hemant et al. (2003) Inducing a change in the pharmacokinetics and biodistribution of poly-L-lysine in rats by complexation with heparin. J Pharm Pharmacol 55:1083-90
Johnston, Thomas P; Salamat-Miller, Nazila T; Alur, Hemant H et al. (2003) An attempt to modulate the microporous diffusion of a model polypeptide by altering its secondary structure. Drug Deliv 10:65-72
Dey, Surajit; Anand, Banmeet S; Patel, Jignesh et al. (2003) Transporters/receptors in the anterior chamber: pathways to explore ocular drug delivery strategies. Expert Opin Biol Ther 3:23-44
Anand, Banmeet S; Dey, Surajit; Mitra, Ashim K (2002) Current prodrug strategies via membrane transporters/receptors. Expert Opin Biol Ther 2:607-20
Chittchang, Montakarn; Salamat-Miller, Nazila; Alur, Hemant H et al. (2002) Poly(L-lysine) as a model drug macromolecule with which to investigate secondary structure and microporous membrane transport, part 2: diffusion studies. J Pharm Pharmacol 54:1497-505
Kuchimanchi, K R; Gandhi, M D; Sheta, R R et al. (2002) Intestinal absorption and biodistribution of cosalane and its amino acid conjugates: novel anti-HIV agents. Int J Pharm 231:197-211
Chittchang, Montakarn; Alur, Hemant H; Mitra, Ashim K et al. (2002) Poly(L-lysine) as a model drug macromolecule with which to investigate secondary structure and membrane transport, part I: Physicochemical and stability studies. J Pharm Pharmacol 54:315-23
Santhosh, K C; Paul, G C; De Clercq, E et al. (2001) Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores. J Med Chem 44:703-14
Kuchimanchi, K R; Ahmed, M S; Johnston, T P et al. (2001) Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein. J Pharm Sci 90:659-66
Tirucherai, G S; Yang, C; Mitra, A K (2001) Prodrugs in nasal drug delivery. Expert Opin Biol Ther 1:49-66

Showing the most recent 10 out of 24 publications